Khiron Welcomes Dr. Eduardo Faveret as Medical Director for Brazil

USA - English

• Brazil - Português

• In 2013, Dr. Faveret became one of the first Brazilian physicians to prescribe medical cannabis, subsequently treating more than 3,000 patients with various conditions across the country
• As Medical Director for Zerenia™, Dr. Faveret will lead patient prescriptions, physician outreach and education, and data-driven product development for Khiron in Brazil, leveraging relationships and deep medical cannabis expertise developed throughout 30-year career
• Khiron positioned to expand Zerenia™ clinics in key cities in Brazil following addition of Medical Director and first sales in Brazil in early July, leveraging Brazilian marketing agreements and production, distribution, and clinical assets in Latin America
• Brazil is Latin America's largest addressable market, with over 200 million people and the potential to reach USD$1.4 billion in annual revenues (Source: New Frontier Data)

TORONTO, July 29, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN)(OTCQX:KHRNF)(Frankfurt:A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the addition of renowned physician, pediatric neurologist and clinical physiologist, Dr. Eduardo Faveret, as Medical Director for Zerenia™ Brazil. As the Company expands its global leadership position, the addition of Dr. Faveret represents a major milestone toward bringing Khiron's market validated clinic strategy to larger markets in Latin America.

Dr. Eduardo Faveret, Medical Director Zerenia™ Brazil
Dr. Faveret is a prominent advocate for medical cannabis in Brazil and a leading prescriber in the country of more than 200 million people. In 2013, Dr. Faveret became one of the first physicians in Brazil to prescribe medical cannabis extract to a child, subsequently treating more than 3,000 patients with conditions such as Alzheimer's, Parkinson's, MS, cancer, anxiety, depression, insomnia, Tourette's syndrome, autism, and chronic pain, among others.

Dr. Faveret boasts a highly distinguished medical and academic career, as the founder and former medical director of the Epilepsy Center at the Paulo Niemeyer State Brain Institute in Rio de Janeiro. He completed post-graduate studies in Pediatric Neurology (Federal University of Rio de Janeiro and FIOCRUZ) and specialized in Clinical Neurophysiology and Epileptology in Bonn Universität and Bethel Epilepsie Zentrum in Germany.

Management Commentary
Alvaro Torres, Khiron CEO and Director, commented: "We are thrilled to welcome Dr. Faveret to our team. With over eight years' experience helping patients access medical cannabis, Dr. Faveret is a leading medical cannabis specialist in Brazil who shares our mission of improving patients' lives through medical cannabis. With the goal of establishing ourselves as the dominant B2C medical cannabis company in Latin America and Europe, and having proven our ability to supply Khiron-branded product to Brazilian patients, we look forward to working with Dr. Faveret to deliver our proven vertically integrated strategy in Latin America's largest market."

About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.

Related Links

https://khiron.ca/